Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial  

Oleh:

Chetchotisakd, Ploenchan ; Kuse, Ernst-Rüdiger ; Cunha, Clovis Arns da ; Ruhnke, Markus ; Barrios, Carlos ; Raghunadharao, Digumarti ; Sekhon, Jagdev Singh ; Freire, Antonio ; Ramasubramanian, Venkatasubramanian ; Demeyer, Ignace ; Nucci, Marcio ; Leelarasamee, Amorn ; Jacobs, Frédérique ; Decruyenaere, Johan ; Ullmann, Andrew J. ; Ostrosky-Zeichner, Luis ; Lortholary, Olivier ; Diekmann-Berndt, Heike ; Cornely, Oliver A

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The Lancet (keterangan: ada di Proquest) vol. 369 no. 9572 (May 2007), page 1519.

Ketersediaan

Perpustakaan FK Nomor Panggil: L01.K.2007.03 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Background: Invasive candidosis is increasingly prevalent in seriously ill patients. Our aim was to compare micafungin with liposomal amphotericin B for the treatment of adult patients with candidaemia or invasive candidosis. Methods: We did a double-blind, randomised, multinational non-inferiority study to compare micafungin (100 mg/day) with liposomal amphotericin B (3 mg/kg per day) as first-line treatment of candidaemia and invasive candidosis. The primary endpoint was treatment success, defined as both a clinical and a mycological response at the end of treatment. Primary analyses were done on a per-protocol basis. This trial is registered with ClinicalTrials.gov, number NCT00106288. Findings: 264 individuals were randomly assigned to treatment with micafungin; 267 were randomly assigned to receive liposomal amphotericin B. 202 individuals in the micafungin group and 190 in the liposomal amphotericin B group were included in the per-protocol analyses. Treatment success was observed for 181 (89·6%) patients treated with micafungin and 170 (89·5%) patients treated with liposomal amphotericin B. The difference in proportions, after stratification by neutropenic status at baseline, was 0·7% (95% CI -5·3 to 6·7). Efficacy was independent of the Candida spp and primary site of infection, as well as neutropenic status, APACHE II score, and whether a catheter was removed or replaced during the study. There were fewer treatment-related adverse events—including those that were serious or led to treatment discontinuation—with micafungin than there were with liposomal amphotericin B. Interpretation: Micafungin was as effective as—and caused fewer adverse events than—liposomal amphotericin B as first-line treatment of candidaemia and invasive candidosis.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali